Vision Improvement for Patients With Age-Related Macular Degeneration

VIS, Inc.0 sites200 target enrollmentJanuary 1, 2024

Overview

Brief Summary

This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Detailed Description

This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Registry

clinicaltrials.gov

Start Date

January 1, 2024

End Date

June 30, 2026

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

VIS, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who meet all of the following criteria are candidates for this study:
•Male or Female
•Patient is at least 50 years old.
•Patient has diagnosed end stage dry or wet age-related macular degeneration in one or both eyes, as verified by a complete ocular examination.
•Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.
•Patient has manifest refraction, spherical equivalent (MRSE) between -1.50 D to 1.50 D in eye(s) to be treated.
•Patient has moderate to severe vision impairment due to age-related macular degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20/80 or worse (decimal less than or equal to 0.25; logMAR ≥ 0.60).in the better eye.
•Patient has CDVA of 20/400 or better (decimal greater than or equal to 0.05; logMAR ≤ 1.30) in the worse eye.
•Patient is not a contact lens (CL) wearer.
•Patient is willing and able to comply with all examinations.

Exclusion Criteria

•Subjects who meet any of the following criteria are to be excluded from this study:
•Corneal disease or corneal disorder in either eye.
•Pathological retinal morphology in either eye that completely affects the entire 10° (3 mm diameter) of the retina centered on the foveola.
•Gonzalez-Markowitz chart Potential Visual Acuity (PVA) in the eye to be treated that is not improved by at least four lines compared to CDVA;
•Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma;
•Previous corneal surgery in the eye to be treated; and
•Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.